PharmaPoint:克隆氏症 - 中國的醫藥品預測與市場分析
PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 99 Pages
|PharmaPoint:克隆氏症 - 中國的醫藥品預測與市場分析 PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022|
|出版日期: 2014年01月31日||內容資訊: 英文 99 Pages||
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
Based on GlobalData's primary research, the majority of Chinese gastroenterologists follow the ACG and/or the World Gastroenterology Organization (WGO) guidelines for the management of their CD patients. In a few cases, they also refer to the local treatment guidelines. Approximately 40% of the referrals for CD patients come from PCPs, while the rest arise from their colleagues or colorectal surgeons..